What is the 13F Pro Quality Score for ENTX?

13F Pro ranks Entera Bio Ltd. (ENTX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ENTX's current score at https://13fpro.ai/company/ENTX (free sign-up required for the full ranking).

Which hedge funds own the most ENTX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ENTX include Knoll Capital Management,, BVF /IL, Siren, L.L.C.. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/ENTX as soon as new 13F filings post.

Where does 13F Pro source ENTX data?

All Entera Bio Ltd. fundamentals and ownership data come directly from SEC EDGAR. Entera Bio Ltd. files with the SEC under CIK 1638097. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ENTX in?

Entera Bio Ltd. (ENTX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ENTX research updated on 13F Pro?

ENTX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Entera Bio Ltd.(ENTX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1638097 ENTX stock profile & AI dashboard →

13F Pro Quality Score

17.0/100

Rank #2,831 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ENTX Scores 17/100

exact factor attribution · 2026-09-11

ENTX's composite is held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings growth

-1.0 pts

30th pct

Earnings quality

-1.0 pts

40th pct

Institutional flow

-2.3 pts

4th pct

Shareholder dilution

-2.5 pts

1th pct

Scale

-3.0 pts

30th pct

Revenue growth

-4.0 pts

30th pct

Capital efficiency

-4.5 pts

5th pct

Profitability

-7.4 pts

1th pct

Free cash flow

-7.4 pts

1th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

ENTX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Entera Bio Ltd. (ENTX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ENTX at 17.0/100 on a 32-signal composite quality model, placing it at rank #2,831 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Entera Bio Ltd. reports net income of $-7.3M, free cash flow of $-3.5M. Top institutional holders of ENTX by reported 13-F value include Knoll Capital Management, BVF, Siren, L.L.C., based on the most recent SEC filings. ENTX trades on the Nasdaq exchange and files with the SEC under CIK 1638097. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ENTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Entera Bio Ltd. directly from SEC EDGAR.

Revenue

Q2 2026

$0.00

Net Income

Q2 2026

$-7.3M

Free Cash Flow

Q2 2026

$-3.5M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-76.8% YoY

$42.0KFY 2025

FY22 $134.0KFY23 $0.00FY24 $181.0KFY25 $42.0K

Net Income

-19.9% YoY

$-11.4MFY 2025

FY22 $-13.1MFY23 $-8.9MFY24 $-9.5MFY25 $-11.4M

Operating Income

-20.3% YoY

$-11.5MFY 2025

FY22 $-13.0MFY23 $-8.9MFY24 $-9.6MFY25 $-11.5M

EPS (Diluted)

+0.0% YoY

$0.25FY 2025

FY22 $0.45FY23 $0.31FY24 $0.25FY25 $0.25

Total Assets

+70.3% YoY

$16.0MFY 2025

FY22 $13.1MFY23 $11.8MFY24 $9.4MFY25 $16.0M

Op. Cash Flow

-8.1% YoY

$-7.4MFY 2025

FY22 $-12.5MFY23 $-7.3MFY24 $-6.8MFY25 $-7.4M

Free Cash Flow

-9.6% YoY

$-7.5MFY 2025

FY22 $-12.5MFY23 $-7.3MFY24 $-6.8MFY25 $-7.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$42.0K -76.8%	$181.0K	$0.00 -100.0%	$134.0K -76.5%	$571.0K +56.4%	$365.0K
Net Income	$-11.4M -19.9%	$-9.5M -7.3%	$-8.9M +32.0%	$-13.1M -7.3%	$-12.2M -8.7%	$-11.2M
Operating Income	$-11.5M -20.3%	$-9.6M -7.8%	$-8.9M +31.7%	$-13.0M -6.5%	$-12.2M -9.4%	$-11.2M
EPS (Diluted)	$0.25 +0.0%	$0.25 -19.4%	$0.31 -31.1%	$0.45 -4.3%	$0.47	—
Total Assets	$16.0M +70.3%	$9.4M -20.2%	$11.8M -10.4%	$13.1M -49.5%	$26.0M +167.3%	$9.7M
Operating Cash Flow	$-7.4M -8.1%	$-6.8M +6.7%	$-7.3M +41.5%	$-12.5M -37.9%	$-9.1M +14.2%	$-10.6M
Free Cash Flow	$-7.5M -9.6%	$-6.8M +6.9%	$-7.3M +41.6%	$-12.5M -38.2%	$-9.1M +14.4%	$-10.6M

Get alerted when ENTX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Entera Bio Ltd. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ENTX

Knoll Capital Management, LLC
$10.4M5,881,879 sh
BVF INC/IL
$4.3M2,425,000 sh
Siren, L.L.C.
$1.3M736,457 sh
RENAISSANCE TECHNOLOGIES LLC
$652.9K368,847 sh
Parkman Healthcare Partners LLC
$485.9K274,497 sh
PNC FINANCIAL SERVICES GROUP, INC.
$483.3K273,031 sh
Seven Fleet Capital Management LP
$338.7K191,354 sh
HighTower Advisors, LLC
$132.9K74,573 sh
HRT FINANCIAL LP
$128.0K72,486 sh
Schonfeld Strategic Advisors LLC
$104.2K58,871 sh

Fund	Value	Shares
Knoll Capital Management, LLC	$10.4M	5,881,879
BVF INC/IL	$4.3M	2,425,000
Siren, L.L.C.	$1.3M	736,457
RENAISSANCE TECHNOLOGIES LLC	$652.9K	368,847
Parkman Healthcare Partners LLC	$485.9K	274,497
PNC FINANCIAL SERVICES GROUP, INC.	$483.3K	273,031
Seven Fleet Capital Management LP	$338.7K	191,354
HighTower Advisors, LLC	$132.9K	74,573
HRT FINANCIAL LP	$128.0K	72,486
Schonfeld Strategic Advisors LLC	$104.2K	58,871

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ENTX on your watchlist

Track score changes the day Entera Bio Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ENTX a good stock to buy?

13F Pro's AI-powered analysis of Entera Bio Ltd. (ENTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ENTX are available on the ENTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ENTX is classified as a small company.

Which hedge funds own ENTX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ENTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Entera Bio Ltd.'s investment landscape.